drugset / Trial / NCT00673218

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

NCT00673218

Phase 4 Unknown 25 enrolled Creighton University Novartis · collab
RandomizedParallel-groupTriple-blindBasic science

Summary

If you are allergic to ragweed, and not taking certain medications, you will be asked to have blood drawn. We will perform experiments on your blood cells.

Timeline

Start
2007-06
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody 150 mg Subcutaneous
Subject Omalizumab Monoclonal antibody 375 mg Subcutaneous

Indications